Chris Aiken, MD.

What You Need to Know About Gepirone (Exxua) | Benefits, Side Effects, and Review of Trials

September 27, 2024

In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists.

Stimulant Dosing Limits for ADHD: When Is The Adderall / Ritalin Dose Too High?

September 18, 2024

Chris Aiken, MD., Kelvin Quiñones-Laracuente, MD, PhD, and Greg Malzberg, MD

In this video, we aim to break down where the safe upper limits lie for stimulant dosing, what to consider when increasing doses, and why crossing certain thresholds can lead to serious risks. We start by discussing why increasing stimulant doses beyond a certain point can be dangerous.

Vilazodone Review | Mechanism • Faster Onset? • Better for Anxiety? • Sexual Side-effects?

August 14, 2024

Chris Aiken, MD. and Greg Malzberg, MD

Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?

Auvelity (Dextromethorphan and Bupropion) | A Fast Acting Antidepressant?

August 12, 2024

Chris Aiken, MD. and Greg Malzberg, MD

We’re taking a deep dive into Auvelity, a new antidepressant that combines Dextromethorphan and Bupropion. While Bupropion is well-established in the treatment of depression, Dextromethorphan is less familiar in psychiatric contexts.

Bipolar Upgrade 3: Lurasidone

August 7, 2023

Chris Aiken, MD. and Kellie Newsome, PMHNP

Lurasidone (Latuda) has gone generic. Find out where this antipsychotic fits in bipolar disorder with updates from the 2023 International Bipolar Conference.

Slow Fade: Homosexuality and the DSM Part 1

June 26, 2023

Chris Aiken, MD. and Kellie Newsome, PMHNP

50 years ago the APA removed code 302.0: Homosexuality from the DSM. Almost.

How to Prescribe Omega-3 Fatty Acids

March 4, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.

A Longer Acting Lorazepam

March 4, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report.

The straight facts on Loreev, a new extended-release formulation of lorazepam (Ativan).

Lybalvi: The Diet Olanzapine

January 31, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.